Drug Trial Radar · NCT03473743
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
125
Actual
Start
Apr 5, 2018
Primary completion
Sep 30, 2022
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.
Conditions
- Urothelial Carcinoma
Interventions
ErdafitinibDrug
Participants will receive erdafitinib orally.
CetrelimabDrug
Participants will receive cetrelimab by intravenous infusion.
CisplatinDrug
Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
CarboplatinDrug
Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)Time frame: Up to 8 weeks
- Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator AssessmentTime frame: From Day 1 up to 36 months
- Phase 2: Number of Participants With Treatment-emergent Adverse Event (TEAEs)Time frame: From Day 1 up to 36 months
Locations
127 sites in 13 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Aurora, Colorado
Norton Cancer Institute
Louisville, Kentucky
Maryland Oncology Hematology, PA
Rockville, Maryland
Hackensack University Medical Center
Hackensack, New Jersey
Weill Cornell Medical College - NY Presbyterian Hospital
New York, New York
White Plains Hospital Center for Cancer Care
White Plains, New York
Levine Cancer Institute, Carolinas HealthCare System
Charlotte, North Carolina
Toledo Clinic Cancer Centers
Toledo, Ohio
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
Texas Oncology, P.A.
Fort Worth, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Virginia Oncology Associates
Norfolk, Virginia
Brest Regional Oncology Dispensary
Brest, Belarus
Grodno University Hospital
Grodno, Belarus
Gomel Regional Clinical Oncology Dispensary
Homyel, Belarus
State Institution N.N. Alexandrov Republican Scientific and
Lesnoy, Belarus
Minsk city Clinical Oncological Dispensary
Minsk, Belarus
Mogilev Regional Hospital
Mogilev, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
ULB Hôpital Erasme
Brussels, Belgium
Cliniques Universitaires Saint Luc
Brussels, Belgium
Jolimont
Haine-Saint-Paul, Belgium
Az Groeninge
Kortrijk, Belgium
CHU de Liège - Domaine Universitaire du Sart Tilman
Liège, Belgium
AZ Nikolaas - Campus Sint-Niklaas Moerland
Sint-Niklaas, Belgium
GZA Ziekenhuizen- Campus St Augustinus
Wilrijk, Belgium
Fundacao Pio XII
Barretos, Brazil
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, Brazil
Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Oncocentro Servicos Medicos e Hospitalares Ltda - Oncocentro
Fortaleza, Brazil
Oncoclinicas Rio de Janeiro S A
Rio de Janeiro, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
Santo André, Brazil
Institut de Cancerologie de Ouest (ICO) Site Paul Papin
Angers, France
Hopital Saint André
Bordeaux, France
Centre Francois Baclesse
Caen, France
Centre hospitalier Saint Louis
La Rochelle, France
Centre Leon Berard
Lyon, France
APHM Hopital Timone
Marseille, France
Hopital Europeen Georges Pompidou
Paris, France
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.